Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today its full-year 2013 financial results, a $100M debt facility and ongoing progress with IPI-145, the Company’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
“Throughout 2013, Infinity made significant progress with IPI-145, demonstrating broad activity and tolerability across multiple hematologic malignancies,” commented Adelene Q. Perkins, Infinity’s chair and chief executive officer.
Help employers find you! Check out all the jobs and post your resume.
